Thyroid dysfunction in patients with chronic viral hepatitis B and C during alpha interferon therapy

Hepatitis Monthly

Volumn 9, Issue 2, 2009, Pages 110-113

  Ziaee, Amir ^a   Esfehanian, Fatemeh ^b   Alavian, Seyed Moayed ^c   Sarreshtedari, Majid ^a  

^a QAZVIN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hepatitis B; Hepatitis C; Interferon Alfa; Thyroid

Indexed keywords

ALPHA INTERFERON; THYROGLOBULIN ANTIBODY; THYROID ANTIBODY; THYROID PEROXIDASE ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; DISEASE PREDISPOSITION; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; NONHUMAN; SIDE EFFECT; THYROID DISEASE; THYROID FUNCTION TEST; THYROID WEIGHT; THYROIDITIS; TREATMENT DURATION;

EID: 70349300426     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol. 1995; 22 (3): 364-9.
2. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med. 1998; 158 (13): 1445-8.
3. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf). 1996; 44 (6): 635-42.
4. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol. 1995; 132 (5): 587-93.
5. Imagawa A, Itoh N, Hanafusa T, et al. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metab. 1995; 80 (3): 922-6.
6. Fentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL. Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet. 1985; 1 (8438): 1166.
7. Mabee CL, Crippin JS, Lee WM. Review article: interferon and hepatitis C--factors predicting therapeutic outcome. Aliment Pharmacol Ther. 1998; 12 (6): 509-18.
8. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology. 1992; 102 (6): 2155-60.
9. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab. 2004; 89 (8): 3656-61.
10. Roti E, Minelli R, Giuberti T, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med. 1996; 101 (5): 482-7.
11. Baudin E, Marcellin P, Pouteau M, et al. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol (Oxf). 1993; 39 (6): 657-61.
12. Koh LK, Greenspan FS, Yeo PP. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid. 1997; 7 (6): 891-6.
13. Deutsch M, Dourakis S, Manesis EK, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology. 1997; 26 (1): 206-10.